Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

• Hoofdauteurs: Mansour A. Alharbi (Auteur), Fahad Aldosari (Auteur), Ahmed Hasan Althobaiti (Auteur), Faris M. Abdullah (Auteur), Salman Aljarallah (Auteur), Nuha M. Alkhawajah (Auteur), Miteb Alanazi (Auteur), Yazed AlRuthia (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2023-05-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Introduction The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinical outcomes. However, mAbs, such as rituximab, natalizumab, and ocrel...